128 related articles for article (PubMed ID: 11597731)
1. Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells.
Uggla B; Möllgård L; Ståhl E; Mossberg LL; Karlsson MG; Paul C; Tidefelt U
Leuk Res; 2001 Nov; 25(11):961-6. PubMed ID: 11597731
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
4. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
6. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Villman K; Ståhl E; Liljegren G; Tidefelt U; Karlsson MG
Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
10. Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.
Wang Y; Azuma Y; Moore D; Osheroff N; Neufeld KL
Mol Biol Cell; 2008 Oct; 19(10):4076-85. PubMed ID: 18632987
[TBL] [Abstract][Full Text] [Related]
11. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting.
Padget K; Pearson AD; Austin CA
Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037
[TBL] [Abstract][Full Text] [Related]
13. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
Salmena L; Lam V; McPherson JP; Goldenberg GJ
Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.
Wang Y; Coffey RJ; Osheroff N; Neufeld KL
PLoS One; 2010 Apr; 5(4):e9994. PubMed ID: 20368985
[TBL] [Abstract][Full Text] [Related]
15. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
16. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
17. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
18. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells.
Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD
Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Mu XC; Tran TA; Ross JS; Carlson JA
J Cutan Pathol; 2000 May; 27(5):242-8. PubMed ID: 10847549
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells.
Akimitsu N; Kamura K; Toné S; Sakaguchi A; Kikuchi A; Hamamoto H; Sekimizu K
Biochem Biophys Res Commun; 2003 Jul; 307(2):301-7. PubMed ID: 12859955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
